Abstract
Background and Aims: Patients with peripheral arterial disease (PAD) are at high risk of cardiovascular events and limb threatening complications. According to the 2019 ESC/EAS (European Society of Cardiology/European Atherosclerosis Society) guidelines for the management of dyslipidaemia high intensity statins and ezetimibe are recommended for low-density lipoprotein cholesterol control (LDL-C). We assessed the impact of different types of statins on the lipid profile of patients with PAD and its effect on LDL-C target level achievement.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
